In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni raise over $180M in new funding, receive FDA clearance, secure strategic partnerships, and much more on the road to LSI Europe ‘24 in Sintra, Portugal (Sept 16-20).
Received FDA clearance for its LumiNE US software for use in surgical planning. The LumiNE US software transforms 2D patient imaging into immersive 3D models, providing surgeons and medical professionals with enhanced visualization of anatomy and pathology during surgical planning.
Secured $12.2M in a Series A funding round following its recent FDA clearance for its MFM-Pro device, a wearable that monitors maternal and fetal heart rates. The funds will support the company’s commercial expansion and the development and FDA clearance of a second proprietary device.
Secured $20M in equity and venture debt financing following a milestone of more than 10,000 Catalyst total shoulder arthroplasty procedures. The funds will be used to enable the company to expand its distribution channels, invest in talent and training, and introduce new products.
Raised €44M in a Series B funding round co-led by LSI Alumni investors Broadview Ventures and Panakès Partners with strong support from CorFlow’s initial VC investor, 415 Capital. The funds will support the advancement of a novel diagnostic and drug delivery platform for microvascular obstruction in heart attack patients.
Received FDA clearance for its second AI-powered imaging product. The product, DASI Dimensions, uses AI to automatically identify and measure dimensions of cardiac structures from CT scans for pre-procedural planning of structural heart procedures, such as TAVR.
Raised $16M in financing led by BOLD Capital Partners, Supernova Invest, and Sanara Capital. The funds will be used to allow Discure Technologies to make key hires and fully fund its First-in-Human clinical study for its implantable device for the treatment of degenerative disc disease in Canada and Italy.
Secured a $35M venture loan facility from Horizon Technology Finance Corporation. The company will use the loan proceeds to execute strategic commercial and clinical expansion plans for GammaTileⓇ, an FDA-cleared treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms.
Received a strategic investment from Arbevel with support from IRDI Capital Investissement and GSO Innovation to fuel its US growth, advance AI innovations, and accelerate global expansion. Medinbox developed a real-time, smart collaboration system for operating rooms and labs.
Received a strategic investment from Springhood Ventures to accelerate its solutions that aim to improve newborn outcomes. NeoPrediX is a predictive analytics company developing proprietary algorithms to forecast the risk of various health conditions under the neonatal, maternal, and perinatal umbrella.
Successfully completed 50 surgeries using its innovative AI-powered surgical guidance platform, Paradigm. The Paradigm system leverages AI, advanced computer vision sensors, and AR/VR to provide critical information, unifying pre-operative imaging and planning with intraoperative performance data.
Announced that the first eight patients were enrolled in the first-in-human INSPECT study of its novel microsensor technology. The company’s sensing technology combines impedance-based microsensors with ML algorithms to instantly identify biological tissues upon contact.
Raised $50M in a Series B funding round to drive commercial expansion and product additions to the HyperVue™ Imaging System. The HyperVue™ Imaging System combines next-generation DeepOCT™ with near-infrared spectroscopy with workflows optimized for the cardiac cath lab.
Received a follow-on investment from Series A investors. VESTECK’s Suture-Tight™ Catheter and Suture secure endovascular aortic grafts to the aorta at the time of the initial implant or repair procedure.
Announced a strategic partnership with Firefly Neuroscience. Under the agreement, Firefly will act as a non-exclusive distributor of Zeto’s FDA-cleared headset devices, cloud platform, and services. The collaboration will also integrate Firefly’s proprietary Brain Network Analytics (BNA™) technology with Zeto’s advanced EEG platform.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
